Abstract
The possible estrogenic effects of tamoxifen on plasma lipids and antithrombin III levels were investigated in 91 breast cancer patients. Mean values of total, HDL and LDL cholesterol, triglycerides, glucose, uric acid, and antithrombin III were evaluated in 55 patients on adjuvant tamoxifen for at least 3 months and compared with those found in 36 patients on no therapy. Total cholesterol, LDL cholesterol, and antithrombin III levels were significantly lower in treated patients (p<0.05).
Our results support the hypothesis of a partial agonist action of this antiestrogen, although general clinical practice suggests that tamoxifen-related thrombotic events are rare.
This is a preview of subscription content, log in via an institution to check access.
References
Rossner S, Wallgren A: Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 52: 339–346, 1984
Enck RE, Rios CN: Tamoxifen treatment of metastatic breast cancer and antithrombin III levels. Cancer 53: 2607–2609, 1984
Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18: 499–502, 1972
Dixon WJ: BMDP Statistical Software. University of California, Berkeley, 1981
Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustration of cases. Lancet 2: 102–104, 1896
Proceedings of the NIH Consensus Development Conference on Adjuvant Chemotherapy and Endocrine Therapy for Breast Cancer. NCI Monographs 1, 1986
Patterson JS, Battersby LA, Edwards DG: Review of the clinical pharmacology and international experience with tamoxifen in advanced breast cancer. Rev Endocrine Related Cancer, Suppl 9: 563–582, 1982
Jordan VC, Fritz NF, Tormey DC: Long-term adjuvant therapy with tamoxifen: effects on Sex Hormone Binding Globulin and Antithrombin III. Cancer Res 47: 4517–4519, 1987
Jacquot C, Graterol R, Bariety J, Capron L, Fiessinger JN: DES versus tamoxifen in advanced breast cancer (Letter). N Engl J Med 304: 1042, 1981
Nevasaari K, Heikkinen M, Taskinen PJ: Tamoxifen and thrombosis (Letter). Lancet 2: 946–947, 1978
Hendrick A, Subramanian VP: Tamoxifen and thromboembolism (Letter). JAMA 243: 514–515, 1980
Lipton A, Harvey HA, Hamilton RW: Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep 68: 887–889, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bertelli, G., Pronzato, P., Amoroso, D. et al. Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels. Breast Cancer Res Tr 12, 307–310 (1988). https://doi.org/10.1007/BF01811244
Issue Date:
DOI: https://doi.org/10.1007/BF01811244